Skip to main content
. 2018 Sep 13;10:3521–3532. doi: 10.2147/CMAR.S172332

Table 2.

The correlation between mRNA levels of E2Fs and clinical and molecular criteria of BC patients

Criteria E2F1 E2F2 E2F3 E2F4 E2F5 E2F6 E2F7 E2F8

No.a mRNA P-value mRNA P-value mRNA P-value mRNA P-value mRNA P-value mRNA P-value mRNA P-value mRNA P-value
Age
≤51 1,361 0.9623 0.0284 <0.0001 0.5265 0.0377 0.0004 0.8497 0.3461
>51 2,142
Nodal status
2,447 0.4376 0.1055 0.7359 0.2055 0.0246 0.8244 0.1139 0.1536
+ 1,509
ER (IHC)
1,525 <0.0001 <0.0001 <0.0001 0.0001 <0.0001 0.4174 <0.0001 <0.0001
+ 3,923
PR (IHC)
946 <0.0001 <0.0001 <0.0001 0.0097 0.0919 0.0282 0.0002 <0.0001
+ 1,439
HER2 (IHC)
1,409 0.0083 0.3372 0.0293 0.8335 0.6897 0.9495 0.0012 <0.0001
+ 201
Triple-negative BC (TNBC)
Not 4,099 <0.0001 <0.0001 <0.0001 0.9164 0.0007 0.8832 0.0251 <0.0001
TNBC 374

Note:

a

The number of patients was based on the group of E2F1 and the exact number of patients in other groups may be a little different.

Abbreviations: E2Fs, E2F transcription factors; BC, breast carcinoma; ER, estrogen receptor; IHC, immunohistochemistry; PR, progesterone receptor.